NIH Funding Opportunities
Notice of Termination of PAR-11-188 Support of NIAMS Program Project Grants (P01)
Notice NOT-AR-13-019 from the NIH Guide for Grants and Contracts
updated: Mon, 13 May 2013 12:00:00 EST
Notice of Change to Funds Available and Anticipated Number of Awards for RFA-FD-13-022 Postmarketing Surveillance of Generic Drug Usage and Substitution Patterns (U01)
Notice NOT-FD-13-007 from the NIH Guide for Grants and Contracts
updated: Fri, 17 May 2013 12:00:00 EST
Notice of Change to Funds Available and Anticipated Number of Awards for RFA-FD-13-020 Collection of Dose Adjustment and Therapeutic Monitoring Data to Aid Narrow Therapeutic Index Drug Classification (U01)
Notice NOT-FD-13-009 from the NIH Guide for Grants and Contracts
updated: Fri, 17 May 2013 12:00:00 EST
Notice of Change to Funds Available and Anticipated Number of Awards for RFA-FD-13-019 Evaluation of Dissolution Methods for Complex Parenteral Dosage Forms (U01)
Notice NOT-FD-13-010 from the NIH Guide for Grants and Contracts
updated: Fri, 17 May 2013 12:00:00 EST
Notice of Clarification of the Scope of Research Projects Encouraged by PAR-13-207 Biophysical and Biomechanical Aspects of Embryonic Development (R01)
Notice NOT-HD-13-005 from the NIH Guide for Grants and Contracts
updated: Fri, 17 May 2013 12:00:00 EST
New Requirements for Applications Submitted to PA-12-114: Infrastructure Development Program in Patient-Centered Outcomes Research (PCOR) (R24) regarding Advance Permission for Eligibility and Detailed Budget Request
Notice NOT-HS-13-008 from the NIH Guide for Grants and Contracts
updated: Wed, 15 May 2013 12:00:00 EST
AHRQ Announces Interest in Research to Improve Diagnostic Performance in Ambulatory Care Settings
Notice NOT-HS-13-009 from the NIH Guide for Grants and Contracts
updated: Fri, 17 May 2013 12:00:00 EST
Notice of Participation of Additional NIH Institutes and Centers in PAR-13-208 Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01)
Notice NOT-NS-13-029 from the NIH Guide for Grants and Contracts
updated: Tue, 14 May 2013 12:00:00 EST
Notice of Correction for PAR-13-131 Understanding and Promoting Health Literacy (R03)
Notice NOT-OD-13-066 from the NIH Guide for Grants and Contracts
updated: Fri, 17 May 2013 12:00:00 EST
Change in the Application Due Date for RFA-OD-13-199 NIH Administrative Supplements to Recover Losses Due to Hurricane Sandy Under the Disaster Relief Appropriations Act - Non-Construction (Admin Supp)
Notice NOT-OD-13-067 from the NIH Guide for Grants and Contracts
updated: Thu, 16 May 2013 12:00:00 EST
Findings of Research Misconduct
Notice NOT-OD-13-068 from the NIH Guide for Grants and Contracts
updated: Fri, 17 May 2013 12:00:00 EST
Update on Budget Format to Use for Applications to PAR-13-129
Notice NOT-OH-13-011 from the NIH Guide for Grants and Contracts
updated: Wed, 15 May 2013 12:00:00 EST
Update on Budget Format to Use for Applications to PAR-12-200
Notice NOT-OH-13-012 from the NIH Guide for Grants and Contracts
updated: Wed, 15 May 2013 12:00:00 EST
Update on Budget Format to Use for Applications to PAR-12-252
Notice NOT-OH-13-013 from the NIH Guide for Grants and Contracts
updated: Wed, 15 May 2013 12:00:00 EST
National Consumer Food Safety Education Conference (U13)
Funding Opportunity RFA-FD-13-003 from the NIH Guide for Grants and Contracts. The purpose of the National Consumer Food Safety Education Conference is to advance the knowledge, practice and effectiveness of health and food safety educators in support of two Healthy People 2020 goals: FS-1: To reduce infections caused by key pathogens transmitted commonly through food FS-5: To increase the proportion of consumers who follow key food safety practices The proposed conference follows on prior successful conferences (1997, 2002, 2006, and 2010) that were jointly sponsored by the US Department of Agriculture, Food Safety and Inspection Service, and the Food and Drug Administration for the purposes of enhancing public education and outreach to improve food handling practices, and for strengthening collaboration among internal and external stakeholders to prevent foodborne illness.
updated: Wed, 15 May 2013 12:00:00 EST
Collaborating Centers of Excellence in Regulatory Science and Innovation (U01)
Funding Opportunity RFA-FD-13-034 from the NIH Guide for Grants and Contracts. As part of the FDA's Advancing Regulatory Science Initiative, the Office of Chief Scientist supports innovation to improve the development of new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of all FDA-regulated products. This Funding Opportunity Announcement (FOA) will provide support for one or more Collaborating Centers of Excellence in Regulatory Science and Innovation (CERSI). The CERSI's will be established to foster an innovative and thematically coherent approach to advance the field of regulatory science (including laboratory, population, behavioral, and manufacturing sciences) and the Critical Path Initiative toward more effective and efficient product development and evaluation.
updated: Wed, 15 May 2013 12:00:00 EST
Pediatric Critical Care and Trauma Scientist Development Program (K12)
Funding Opportunity RFA-HD-14-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support a national program of mentored advanced career development and training in research for junior faculty in pediatric critical care medicine and pediatric trauma surgery at research-intensive institutions.
updated: Thu, 16 May 2013 12:00:00 EST
Clinical Centers (CC) for the NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network (U01)
Funding Opportunity RFA-HL-14-014 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is for Clinical Centers (CC) for a new National Heart, Lung, and Blood Institute (NHLBI) Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury (ALI) (PETAL Network). The Network will consist of approximately 11 CCs and 1 Clinical Coordinating Center (CCC). The Network will develop and conduct at least 3-5 randomized controlled clinical trials to prevent, treat, and/or improve the outcome of adult patients with, or at risk for, ALI or the acute respiratory distress syndrome (ARDS). Each CC will be expected to enroll 220 patients over 5.5 years. This FOA solicits applications for CCs and runs parallel with a separate FOA for the CCC (RFA-HL-14-015.
updated: Wed, 15 May 2013 12:00:00 EST
Clinical Coordinating Center (CCC) for the NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network (U01)
Funding Opportunity RFA-HL-14-015 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) is for a Clinical Coordinating Center (CCC) for a new National Heart, Lung, and Blood Institute (NHLBI) Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury (ALI) (PETAL Network). The Network will consist of approximately 11 Clinical Centers and 1 CCC. The Network will develop and conduct randomized controlled clinical trials to prevent, treat, and/or improve the outcome of adult patients with, or at risk, for ALI or the Acute Respiratory Distress Syndrome (ARDS). This FOA solicits applications for a CCC and runs parallel with a separate FOA for the CCs (RFA-HL-14-014). These awards are expected to be for 7 years.
updated: Wed, 15 May 2013 12:00:00 EST
Research on the Role of Epigenetics in Social, Behavioral, Environmental and Biological Relationships, throughout the Life-Span and across Generations (R21)
Funding Opportunity RFA-TW-13-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages exploratory and developmental grant applications to lay the foundation for innovative and collaborative basic research on the role of epigenetics in social, behavioral, environmental and biological relationships, throughout the life-span and across generations. Research plans that are responsive to this FOA will use existing bio-psycho-social and environmental data from human cohorts or animal studies that have biospecimens available for epigenetic profiling. The one year exploratory/developmental awards are expected to generate preliminary data for comprehensive basic research applications to study interactions between epigenetics and social/behavioral/biological/environmental factors in both normal function and pathophysiology throughout life and across generations. The results may ultimately inform research to develop clinical decision/diagnostic tools and prevention/treatment strategies.
updated: Fri, 17 May 2013 12:00:00 EST
Evidence-based Demonstration Projects in Immunization (Admin Supp)
Funding Opportunity PA-13-226 from the NIH Guide for Grants and Contracts. The National Institute on Minority Health and Health Disparities (NIMHD) and the National Vaccine Program Office (NVPO), Office of the Assistant Secretary for Health, Office of the Secretary, DHHS, announce the availability of funds to support administrative supplements to current NIMHD R01 grantees and those funded under the Centers of Excellence (COE) program (P20 or P60 mechanism), Research Centers in Minority Institutions (RCMI) program (G12 or U54 mechanism), and Community-based Participatory Research Initiative (R24) to support evidence-based demonstration projects designed to decrease infectious diseases by stimulating immunization rate improvements of children, adolescents, pregnant women and adults in one or more health disparity populations.
updated: Thu, 16 May 2013 12:00:00 EST
Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the NIDDK Repository (R01)
Funding Opportunity PAR-13-228 from the NIH Guide for Grants and Contracts. This FOA will provide support for assays (and associated data analysis) of repository-held samples for studies focused on an NIDDK-relevant disease. The review of applications to this FOA will consider both access to repository-held samples and funding for assays using the samples. These studies are expected to generate scientific discoveries on disease mechanisms, disease pathogenic processes, disease progression, or clinical responses. Projects that make good use of the associated data from the clinical trials and studies, the original intent of the clinical study and/or trial are highly encouraged. Exploratory studies and discovery research are encouraged especially when samples are not severely limited, the work is justified, and the goal is consistent with the original intent of the clinical research.
updated: Wed, 15 May 2013 12:00:00 EST